This Month in Gastroenterology

Slides:



Advertisements
Similar presentations
Volume 140, Issue 2, Pages e9 (February 2011)
Advertisements

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.
Covering the Cover Gastroenterology
Volume 145, Issue 2, Pages (August 2013)
Volume 126, Issue 1, Pages (January 2004)
This Month in Gastroenterology
Volume 131, Issue 2, Pages (August 2006)
Liver Fibrosis Protects Mice From Acute Hepatocellular Injury
Volume 151, Issue 2, Pages e12 (August 2016)
Christoph Lübbert, Babett Holler  Gastroenterology 
Volume 139, Issue 4, Pages e4 (October 2010)
Covering the Cover Gastroenterology
This Month in Gastroenterology
Covering the Cover Gastroenterology
This Month in Gastroenterology
Racial Disparity in Gastrointestinal Cancer Risk
This Month in Gastroenterology
Outcomes Among Living Liver Donors
Volume 139, Issue 4, Pages (October 2010)
Volume 134, Issue 1, Pages (January 2008)
Volume 136, Issue 4, Pages (April 2009)
This Month in Gastroenterology
Cause-Specific Mortality of People With Barrett's Esophagus Compared With the General Population: A Population-Based Cohort Study  Masoud Solaymani–Dodaran,
This Month in Gastroenterology
Liver Fibrosis Protects Mice From Acute Hepatocellular Injury
Volume 154, Issue 5, Pages (April 2018)
Volume 137, Issue 3, Pages (September 2009)
Volume 153, Issue 3, Pages e16-e17 (September 2017)
Volume 150, Issue 4, Pages (April 2016)
Volume 140, Issue 2, Pages e9 (February 2011)
This Month in Gastroenterology
Volume 137, Issue 4, Pages (October 2009)
Volume 139, Issue 4, Pages e8 (October 2010)
Covering the Cover Gastroenterology
This Month in Gastroenterology
This Month in Gastroenterology
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Volume 145, Issue 2, Pages (August 2013)
Volume 137, Issue 1, Pages (July 2009)
Volume 133, Issue 4, Pages (October 2007)
This Month in Gastroenterology
Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.
This Month in Gastroenterology
This Month in Gastroenterology
This Month in Gastroenterology
This Month in Gastroenterology
Laura Rotundo, Sushil Ahlawat  Gastroenterology 
Volume 153, Issue 4, Pages (October 2017)
This Month in Gastroenterology
Reduced Mortality Rates Following Elective Percutaneous Liver Biopsies
Volume 133, Issue 2, Pages (August 2007)
Volume 150, Issue 7, Pages (June 2016)
Volume 137, Issue 4, Pages (October 2009)
This Month in Gastroenterology
Covering the Cover Gastroenterology
This Month in Gastroenterology
Covering the Cover Gastroenterology
Baby-Epsilon Steps Toward the Triple Aim
No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002–2014) 
This Month in Gastroenterology
Volume 139, Issue 4, Pages (October 2010)
Daniel Mønsted Shabanzadeh, Lars Tue Sørensen, Torben Jørgensen 
Volume 139, Issue 6, Pages e1 (December 2010)
Volume 138, Issue 6, Pages (May 2010)
Covering the Cover Gastroenterology
Covering the Cover Gastroenterology
Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis  Russell F. Jacoby, Carolyn E.
This Month in Gastroenterology
Volume 118, Issue 6, Pages (June 2000)
This month in Gastroenterology
Presentation transcript:

This Month in Gastroenterology Jan Tack, John M. Carethers  Gastroenterology  Volume 139, Issue 4, Pages 1069-1072 (October 2010) DOI: 10.1053/j.gastro.2010.08.007 Copyright © 2010 AGA Institute Terms and Conditions

Figure 1 (A) Proportions of total diarrhea morbidity accounted for by acute (<7 days), prolonged (7–13 days), and persistent (≥14 days) episodes and by days of illness. (B) Proportional hazard curves of time to first persistent diarrhea (≥14 days) episode in children with or without a prolonged episode of diarrhea (7–13 days) in the first year of life. Gastroenterology 2010 139, 1069-1072DOI: (10.1053/j.gastro.2010.08.007) Copyright © 2010 AGA Institute Terms and Conditions

Figure 2 Cumulative incidences of all-cause mortality or rehospitalization for acute coronary syndromes for the clopidogrel plus H2RA cohort, the clopidogrel plus PPI cohort, the clopidogrel alone cohort, the H2RA alone cohort, the and PPI alone cohort. Gastroenterology 2010 139, 1069-1072DOI: (10.1053/j.gastro.2010.08.007) Copyright © 2010 AGA Institute Terms and Conditions

Figure 3 Phospho-sulindac (P-S) is a safe and effective antitumor agent against colon cancer in vivo. (A) Acute gastrointestinal toxicity of sulindac and P-S. Rats were treated with P-S, sulindac, indomethacin or vehicle and at day 5, the number and sizes of small intestinal ulcerations were counted and scored. (B) Survival curve for mice treated daily for 3 weeks with equimolar doses of P-S or sulindac. (C) Effect of P-S and sulindac on colon cancer xenografts in nude mice. Left panel: Tumor volume growth over time for each treatment. Center panel: Photographs of mouse xenografts. Right panel: Mass of dissected xenographs. All values are means + SEM. *P < .05 versus vehicle-treated mice; #P < .05 versus sulindac-treated mice. Gastroenterology 2010 139, 1069-1072DOI: (10.1053/j.gastro.2010.08.007) Copyright © 2010 AGA Institute Terms and Conditions

Figure 4 FGF-7 activates a cytoprotective response in the liver. FGFR1/2 knockout (ko) mice and control (ctrl) littermates were injected intraperitoneally with saline or 5 μg FGF7. Mice were humanely killed 10 or 30 minutes after injection, and RNAs from the liver were analyzed by qRT-PCR for expression of Dbp and Tef (top panels) or Cyp2a5 and Cyp2c38 (bottom panels). Gastroenterology 2010 139, 1069-1072DOI: (10.1053/j.gastro.2010.08.007) Copyright © 2010 AGA Institute Terms and Conditions